Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
MANGALAMNSE
Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | -27% |
| - | - | - | -761% |
| -15% | -26% | -34% | -56% |
| -13% | -13% | -13% | -37% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
MANGALAM
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,769.9 | ₹424202 Cr | 38.68 | 8.29 | 58.23 | ₹11479 Cr |
| 10,064 | ₹264141 Cr | 90.3 | 34.04 | 128.41 | ₹2568 Cr |
| 4,650 | ₹174402 Cr | 82.11 | 14.04 | 106.21 | ₹2163 Cr |
| 2,323 | ₹126811 Cr | 94.64 | 8.17 | 33.94 | ₹889 Cr |
| 1,240.6 | ₹123685 Cr | 27.41 | 9.42 | 62.53 | ₹5040 Cr |
| 1,368.3 | ₹111868 Cr | 39.95 | 11.08 | 59.2 | ₹4196 Cr |
| 1,396.9 | ₹111650 Cr | 38.54 | 10.86 | 52.6 | ₹3879 Cr |
| 2,475 | ₹102196 Cr | 45.57 | 17.23 | 76.26 | ₹1913 Cr |
| 1,694.5 | ₹96951 Cr | 26.11 | 17.95 | 96.84 | ₹3505 Cr |
| 2,015.9 | ₹91301 Cr | 16.51 | 30.95 | 154.35 | ₹5333 Cr |
| 29.14 | ₹46 Cr | — | -4.83 | -12.89 | -₹44 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹57 Cr | ₹67 Cr | ₹58 Cr | ₹50 Cr | ₹57 Cr | ₹73 Cr | ₹89 Cr | ₹80 Cr | ₹77 Cr | ₹102 Cr | ₹97 Cr |
| ₹11 L | ₹9 L | ₹11 L | ₹3 L | ₹14 L | ₹47 L | ₹14 L | ₹14 L | ₹2 L | ₹5 L | ₹20,000 |
| ₹57 Cr | ₹67 Cr | ₹59 Cr | ₹50 Cr | ₹57 Cr | ₹73 Cr | ₹89 Cr | ₹80 Cr | ₹77 Cr | ₹102 Cr | ₹97 Cr |
| ₹60 Cr | ₹78 Cr | ₹64 Cr | ₹57 Cr | ₹66 Cr | ₹68 Cr | ₹84 Cr | ₹75 Cr | ₹72 Cr | ₹94 Cr | ₹94 Cr |
| ₹1 Cr | -₹6 Cr | -₹1 Cr | -₹3 Cr | -₹4 Cr | ₹10 Cr | ₹9 Cr | ₹9 Cr | ₹8 Cr | ₹12 Cr | ₹7 Cr |
| ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
| -₹7 Cr | -₹13 Cr | -₹10 Cr | -₹12 Cr | -₹13 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹59 L | ₹4 Cr | ₹4 L |
| -₹8 Cr | -₹13 Cr | -₹10 Cr | -₹7 Cr | -₹14 Cr | ₹6 L | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹50 L |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Revaluation reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| — | — | — |
| ₹16 Cr | ₹16 Cr | ₹16 Cr |
| ₹87 Cr | ₹133 Cr | ₹120 Cr |
| ₹80 Cr | ₹126 Cr | ₹120 Cr |
| ₹7 Cr | ₹7 Cr | ₹0 |
| ₹103 Cr | ₹149 Cr | ₹136 Cr |
| ₹4 Cr | ₹9 Cr | ₹12 Cr |
| ₹4 Cr | ₹53 L | ₹91 L |
| ₹5 Cr | ₹10 Cr | ₹12 Cr |
| ₹3 Cr | ₹7 Cr | ₹8 Cr |
| ₹15 Cr | ₹26 Cr | ₹34 Cr |
| — | — | — |
| ₹76 Cr | ₹98 Cr | ₹66 Cr |
| ₹25 Cr | ₹20 Cr | ₹22 Cr |
| ₹95 Cr | ₹71 Cr | ₹75 Cr |
| ₹1 Cr | ₹2 Cr | ₹99 L |
| ₹197 Cr | ₹192 Cr | ₹164 Cr |
| ₹315 Cr | ₹366 Cr | ₹334 Cr |
| ₹10 Cr | ₹35 Cr | ₹12 Cr |
| ₹109 Cr | ₹88 Cr | ₹95 Cr |
| — | — | — |
| ₹299 Cr | ₹288 Cr | ₹261 Cr |
| ₹144 Cr | ₹126 Cr | ₹114 Cr |
| ₹155 Cr | ₹163 Cr | ₹148 Cr |
| ₹0 | ₹1 Cr | ₹0 |
| ₹44,000 | ₹44,000 | ₹44,000 |
| ₹44,000 | ₹44,000 | ₹44,000 |
| ₹28 L | ₹2 Cr | ₹2 Cr |
| ₹159 Cr | ₹167 Cr | ₹158 Cr |
| — | — | — |
| ₹103 Cr | ₹139 Cr | ₹124 Cr |
| ₹40 Cr | ₹39 Cr | ₹28 Cr |
| ₹70 L | ₹3 Cr | ₹1 Cr |
| ₹81 L | ₹2 Cr | ₹2 Cr |
| ₹11 Cr | ₹17 Cr | ₹22 Cr |
| ₹156 Cr | ₹199 Cr | ₹176 Cr |
| -₹41 Cr | ₹7 Cr | ₹12 Cr |
| ₹315 Cr | ₹366 Cr | ₹334 Cr |
| ₹61 | ₹90 | ₹86 |
| ₹61 | ₹90 | ₹86 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| -₹49 Cr | ₹5 Cr | ₹4 Cr |
| ₹33 Cr | ₹31 Cr | ₹14 Cr |
| ₹20 Cr | ₹7 Cr | -₹14 Cr |
| ₹4 Cr | ₹43 Cr | ₹4 Cr |
| ₹4 Cr | ₹43 Cr | ₹4 Cr |
| -₹12 Cr | -₹19 Cr | -₹12 Cr |
| ₹6 Cr | -₹22 Cr | ₹5 Cr |
| -₹2 Cr | ₹1 Cr | -₹3 Cr |
| ₹3 Cr | ₹1 Cr | ₹4 Cr |
| ₹70 L | ₹3 Cr | ₹1 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 6 out of 9 oscillators
RSI
44.16Sell
STOCH %K
23.34Neutral
MACD Level(12,26)
-0.63Sell
Ultimate Oscillator
35.11Sell
Aroon Oscillator
30.00Sell
BOP
-0.88Sell
CCI
-63.97Neutral
Williams %R
-76.66Neutral
Momentum
-2.87Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 1
Bearish signals: 8 out of 9 moving averages
EMA 9
29.30Sell
SMA 9
28.95Buy
EMA 21
29.97Sell
SMA 21
30.34Sell
EMA 50
30.25Sell
SMA 50
31.05Sell
EMA 200
35.41Sell
SMA 200
30.89Sell
WMA 20
29.71Sell
Pivot
Pivot
Classic
Resistance 5
33.61
Resistance 4
32.46
Resistance 3
31.31
Resistance 2
30.16
Resistance 1
29.69
Pivot
29.01
Support 1
28.54
Support 2
27.86
Support 3
26.71
Support 4
25.56
Support 5
24.41
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 35.65% | 35.65% | 35.65% | 35.64% | 50.30% | 50.30% |
| 0.11% | 0.11% | 0.32% | 0.13% | 0.11% | 0.53% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 64.24% | 64.24% | 64.03% | 64.23% | 49.59% | 49.17% |
Bulk & block deals
Name
Neo Apex Venture Llp
Neo Apex Venture Llp
Neo Apex Venture Llp
Sanjay Kumar Saini
Jyotiprasad Taparia
Ashutosh Taparia
Shivkumar Damani
Sanjay Kumar Saini
Epitome Trading And Investments
Epitome Trading And Investments
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 03 Feb 2026 | Sell | 1.33 Cr | ₹37.90 | 3.50 L | Bulk | 2.211243 | NSE |
| 03 Feb 2026 | Sell | 40.20 L | ₹38.01 | 1.06 L | Bulk | 0.66813 | BSE |
| 02 Feb 2026 | Purchase | 1.49 Cr | ₹32.68 | 4.56 L | Bulk | 2.879374 | NSE |
| 13 Jan 2026 | Sell | 38.62 L | ₹40.65 | 95 K | Bulk | 0.600195 | NSE |
| 13 Jan 2026 | Sell | 63.96 L | ₹42.64 | 1.50 L | Bulk | 0.947676 | NSE |
| 12 Jan 2026 | Sell | 81.22 L | ₹40.61 | 2 L | Bulk | 1.263568 | NSE |
| 12 Jan 2026 | Sell | 33.30 L | ₹40.61 | 82 K | Bulk | 0.518056 | NSE |
| 09 Jan 2026 | Purchase | 36.83 L | ₹38.77 | 95 K | Bulk | 0.600195 | BSE |
| 09 Jan 2026 | Sell | 51.98 L | ₹38.77 | 1.34 L | Bulk | 0.846995 | BSE |
| 08 Jan 2026 | Purchase | 36.84 L | ₹36.84 | 1 L | Bulk | 0.631784 | NSE |
Insider trading & SAST
Client name
Shree Resbihari Trading And Investment Private Ltd
Aditya Ramniwas Dhoot
Shree Kishoriju Trading And Investments Private Ltd
Shree Kishoriju Trading And Investment Private Limited
Ajay Ramniwas Dhoot
Shree Rasbihari Trading And Investments Private Limited
Aditya Ramniwas Dhoot
Shree Kishoriju Trading And Investment Private Limited
Shri Jb Pharma Private Limited
Shree Kishoriju Trading And Investments Private Limited (Revised)
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04 May 2026 | Promoter | Pledge | — | — | 0 | — | 1.73 L | 16 Mar 2026 | Release | 0 | SAST | Reg31 | — |
| 04 May 2026 | Promoter | Pledge | — | — | 0 | — | 89 K | 16 Mar 2026 | Release | 0 | SAST | Reg31 | — |
| 04 May 2026 | Promoter | Pledge | 0 | — | 0 | — | 1.50 K | 06 Feb 2026 | Release | 0 | SAST | Reg31 | — |
| 10 Apr 2026 | Promoter Group | Revoke | 0.009477 | 3.21 | 51.47 K | ₹34.31 | 1.50 K | 06 Feb 2026 | Pledge Released | 5,08,599 | Insider Trading | — | Equity Shares |
| 20 Mar 2026 | Promoter Group | Revoke | 0.871862 | 0.88 | 43.76 L | ₹31.71 | 1.38 L | 16 Mar 2026 | Pledge Released | 1,38,687 | Insider Trading | — | Equity Shares |
| 20 Mar 2026 | Promoter | Revoke | 1.092986 | 6.2 | 54.86 L | ₹31.71 | 1.73 L | 16 Mar 2026 | Pledge Released | 9,82,563 | Insider Trading | — | Equity Shares |
| 20 Mar 2026 | Promoter Group | Revoke | 0.562288 | 0.56 | 28.22 L | ₹31.71 | 89 K | 16 Mar 2026 | Pledge Released | 89,225 | Insider Trading | — | Equity Shares |
| 27 Feb 2026 | Promoter | Revoke | 0.868602 | 3.2 | 33.05 L | ₹24.04 | 1.37 L | 22 Dec 2025 | Pledge Released | 5,07,099 | Insider Trading | — | Equity Shares |
| 08 Dec 2025 | Promoter Group | Invoke | 10.740324 | 6 | 6.20 Cr | ₹36.46 | 17 L | 26 Nov 2025 | Invocation Of Pledged | 9,50,000 | Insider Trading | — | Equity Shares |
| 03 Dec 2025 | Promoter | Invoke | 4.605072 | 2.34 | 2.15 Cr | ₹29.54 | 7.29 L | 27 Nov 2025 | Invocation Of Pledged | 3,69,615 | Insider Trading | — | Equity Shares |
Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
Mangalam Drugs and Organics Limited is an India-based company engaged in the manufacturing of chemicals such as active pharma ingredients (API) perfumery disperse dye intermediates bulk drugs and bulk drugs
Corporate Actions
Date
Type
Details
Company details
Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
No presentations found
Mangalam Drugs And Organics Share Price
29.18-0.03 (-0.10%)
-55.38% past 1 Year
News
Mangalam Drugs And Organics flags Rs 15.57 crore loan defaults to banks
Equity
MANGALAM
Mangalam Drugs & Organics informs about secretarial compliance report
Equity
MANGALAM
Mangalam Drugs and Organics informs about newspaper advertisement
Equity
MANGALAM
Mangalam Drugs&Org. reports Profit after tax of Rs -13.06 Crores, in the March 2026 quarter
Equity
MANGALAM
Mangalam Drugs & Organics informs about revised disclosure
Equity
MANGALAM
Mangalam Drugs & Organics informs about resignation of CS
Equity
MANGALAM
Mangalam Drugs & Organics informs about disclosure
Equity
MANGALAM
Mangalam Drugs & Organics informs about disclosure
Equity
MANGALAM
Mangalam Drugs&Org. - Quaterly Results
Equity
MANGALAM
Mangalam Drugs&Org. reports Profit after tax of Rs -9.78 Crores, in the December 2025 quarter
Equity
MANGALAM
Investor Vijay Kedia Acquires 1.38 Lakh Shares in Mangalam Drugs at Rs 24.15 Each.
Equity
MANGALAM
Mangalam Drugs & Organics secures Rs 15 crore export order for anti-malarial API, enhancing global business outlook.
Equity
MANGALAM
Mangalam Drugs&Org. reports Profit after tax of 1.18 Crores, in the September 2025 quarter
Equity
MANGALAM
NCLT Accepts Mangalam Drugs Merger Petition With Mangalam Laboratories and Shri JB Pharma
Equity
MANGALAM
Mangalam Drugs and Organics gains on getting order from international client
Equity
MANGALAM
Mangalam Drugs and Organics gets order from international client
Equity
MANGALAM
Mangalam Drugs&Org. - Quaterly Results
Equity
MANGALAM
Mangalam Drugs&Org. - Quaterly Results
Equity
MANGALAM
Mangalam Drugs&Org. reports Profit after tax of Rs -13.73 Crores, in the June 2025 quarter
Equity
MANGALAM
Mangalam Drugs&Org. reports Profit after tax of 15.10 Lakhs, in the March 2025 quarter
Equity
MANGALAM